Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Novartis presents an attractive profile for investors
1
Clear
strategy
Delivering on
strategy as a focused
medicines company,
powered by
technology platforms.
2
Attractive
growth profile
Confident in 4%+
sales CAGR (2020
to 2026), above peer
median growth
beyond 2026
High 30s IM margin
3
Strong mid/late-
stage portfolio
Breadth and depth,
20+ assets with
USD ≥1bn potential,
fuel further growth
to 2030 and beyond
4
Platform
leadership
Continue to develop
leadership across
TPD, Cell, Gene,
RLT, XRNA platforms
5
Balanced capital
allocation
Aims to combine
investing in core
business and returning
excess capital to
shareholders
TPD Targeted Protein Degradation RLT Radioligand Therapy
5 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation